Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in VHL Disease with Renal Tumors
NCT00566995Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2008
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vandetanib in von Hippel–Lindau disease (VHL), renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Feb 2008; status: completed.
02
Drugs
vandetanib
03
Conditions
von Hippel–Lindau disease (VHL)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00566995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00566995.